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serum 25-hydroxyvitamin D deficiency in adults
with cerebral palsy
Mark D Peterson*, Heidi J Haapala, Ashish Chaddha and Edward A HurvitzAbstract
Background: Individuals with cerebral palsy (CP) are at risk for nutritional insufficiency. The purpose of the study
was to examine the vitamin D status of adults with CP, and to evaluate the association between vitamin D and
functional level, age, race, and anthropometric indicators of adiposity.
Methods: Serum vitamin D levels, BMI, waist circumference (WC), and functional level (measured by Gross Motor
Function Classification System (GMFCS)) were examined in 112 adults with CP. Vitamin D status was assessed by
serum 25-hydroxyvitamin D level (25(OH)D). The influence of motor impairment and adiposity on 25(OH)D were
assessed using general linear modeling and logistic regression, with age, sex, race, and season as covariates.
Results: Mean vitamin D was 28.1 ± 16.0 ng/ml. Only 45% of subjects had optimal levels of 25(OH)D, 21% were
insufficient and 34% were deficient. Overweight or obesity was prevalent (52%), as was abdominal obesity in men
(23.5% at 102 cm cutoff) and women (31.1% at 88 cm cutoff). There was a robust association between the indicator
of visceral adiposity (WC) and 25(OH)D level (p <0.001), even after controlling for age, sex, race, season, and GMFCS.
According to sex-specific WC cutoffs, the odds of being deficient in vitamin D increase by a factor of 3.5 (95% CI
1.12-11.0) for abdominal obesity. GMFCS was not associated with 25(OH)D.
Conclusions: Adults with CP are at risk for low vitamin D levels and overweight/obesity. Waist circumference is a
strong independent predictor for low vitamin D levels.
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Vitamin D plays an important role in a wide range of
organ functions, and is suggested to contribute signifi-
cantly to cardiometabolic and musculoskeletal health.
Vitamin D deficiency is now considered to be an epidemic,
with recent estimates as high as 64% of the general health-
care population [1]. At present there is substantial debate
regarding the optimal level of serum 25-hydroxyvitamin D
(25(OH)D) as well as the efficacy and dosing strategy of
supplemental vitamin D; however, most reports agree that
serum levels less than 20 ng/mL (i.e. 50 nmol/L) may be
insufficient for optimal bone health [2]. Historically consid-
ered an independent predictor of osteoporosis [3] and* Correspondence: mdpeterz@med.umich.edu
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unless otherwise stated.muscle function [4,5], emerging evidence has also linked
vitamin D deficiency with a host of obesity-related comor-
bid conditions such as metabolic syndrome, coronary heart
disease, hyperlipidemia, and diabetes [1,6,7], as well as early
mortality [8]. Indeed, there is now a well-established recip-
rocal association between adiposity and vitamin D, which
may be caused by a decreased bioavailability of and depos-
ition in adipose tissue compartments [9-11] (particularly in
the visceral depot [12,13]).
The reported incidence of vitamin D deficiency is
population specific, and contingent upon various demo-
graphic factors such as age, sex, race and geographical
location (i.e., distance from the equator, and/or loca-
tions wherein foods are not fortified with vitamin D)
[2]. These general characteristics notwithstanding, select
sub-populations such as individuals with congenital or
chronic neuromuscular disorders (e.g., cerebral palsy (CP))al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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osteopenia and impaired bone mass accrual [14], as well as
secondary health complications associated with or exagger-
ated by the combination of insufficient vitamin D [15],
chronic sedentary behavior, and obesity [16]. Although at
present the role of vitamin D on secondary health compli-
cations in CP is unknown, it is certainly conceivable that
degree of motor impairment and abdominal adiposity may
serve as significant predictors for vitamin D status.
However, most clinicians who treat patients with CP
do not check vitamin D levels on a consistent basis.
Considering the inherent feeding difficulties associated
with esophageal reflux, swallowing, and gastric disorders,
many CP patients have poor overall nutrition and insuf-
ficient calcium and vitamin D intake. Although a large
body of research has confirmed a significant association
between nutritional insufficiency, growth, and dimin-
ished musculoskeletal health in CP, patients are also rou-
tinely prescribed anticonvulsant medications that interfere
with calcium and vitamin D absorption, and that further
contribute to low bone mineral density [17]. Moreover,
and in combination with inadequate nutrient intake/
absorption, chronic pain and fatigue in CP represent
two significant barriers for participation in physical activity
and load bearing exercise [18], and thus dramatically in-
crease the likelihood of being sedentary and housebound
with little exposure to sunlight.
The purpose of this study was to examine vitamin D
status among adults with CP, and to determine the asso-
ciations with gross motor function and several anthropo-
metric indicators of adiposity, after adjustment for known
covariates such as age, season, and race. Since degree of
motor impairment is a strong indicator of nutritional insuf-
ficiency and chronic sedentary behavior, we hypothesized
that vitamin D levels would be independently associated
with more severe motor impairment. We also hypothesized
that both BMI and waist circumference would be inde-
pendent predictors of lower serum vitamin D. Certainly,
understanding the independent contributions of motor im-
pairment, as well as a modifiable predictor such as adipos-
ity, on vitamin D status, may better define risk for latent
complications which may exacerbate the CP condition.
Methods
Study design
Patient records were obtained through the University of
Michigan Adult Cerebral Palsy Clinic, Department of
Physical Medicine and Rehabilitation. This retrospective
study included a synthesis of relevant patient descriptive
data, as well as bivariate and regression analyses between
various anthropometric characteristics (i.e., body mass,
height, BMI, waist circumference and hip circumference,
and waist-to-hip ratios), functional status, and serum vita-
min D.Patient population
Male and female participants were 18 years and older,
admitted to University of Michigan adult CP clinic. Pa-
tients in the sample represented a variety of diagnostic
categories for CP, according to the Gross Motor Func-
tion Classification System (GMFCS). The initial sample
consisted of 130 patients’ clinic records that were eligible
for inclusion in the analysis. We excluded records that
did not include sufficient data pertaining to vitamin D sta-
tus and/or general intake patient characteristics such as an-
thropometric measures. The final sample included 112
patient records (52 males, 60 females; age = 34 ± 13.4 years).
Race/ethnicity distribution was primarily Non-Hispanic
white (~90%), as compared to African American (8%)
and Mexican American or other Hispanic (~2%). Each
subject signed an informed consent document and all
procedures were approved by the University of Michigan
Medical institutional review board for research with hu-
man subjects.
Measures
Gross motor function classification system (GMFCS)
The Gross Motor Functional Classification System
(GMFCS) assesses activity limitations for gross motor
function with a five level ordinal grading scale. The
GMFCS in the adult population has been shown to be re-
liable (interclass correlation coefficient (ICC) = 0.93) and
have excellent interrater reliability (quadratic kappa value
of 0.978) [19]. All patients were examined by the same
physician investigator to classify GMFCS level-which was
available upon chart review. The individuals were also
classified into two severity categories: GMFCS levels I-III
and GMFCS levels IV-V, as previously documented [20].
Anthropometric measures
As a part of normal medical intake, each patient was
tested for body mass (kg), height (cm), and body mass
index (BMI-kilograms per squared meters [(kg∙m−2]).
For patients who had difficulty standing erect, supine re-
cumbent length had been measured and was used in-
stead to calculate height. Waist circumference (WC) and
hip circumference (HC) were measured using a standard
Gulick tape, and evaluated to the nearest 0.1 cm. For
WC, a horizontal measure was taken at the narrowest
part of the torso (i.e. below xiphoid process and above
the umbilicus). Standard cutpoints for abdominal obesity
in men (>102 cm) and women (>88 cm) were used, as
outlined by the ATP III report. For HC, horizontal mea-
sures were taken at the site of maximal circumference.
Waist-to-hip ratio (WHR) was also calculated.
Vitamin D status and parathyroid hormone (PTH)
Vitamin D levels were drawn as part of the patients’ clinical
evaluation. Blood samples were drawn by venipuncture
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University of Michigan Clinical Chemistry Laboratories, in
Department of Pathology. Determinations of 25(OH)D
were made in serum by a chemiluminescence immuno-
assay (CLIA) with intra- and interassays variabilities of
4.7% and 7.1% respectively. Vitamin D status was catego-
rized as optimal (≥30 ng/ml), insufficient (21–29 ng/ml),
and deficient (<20 ng/ml), based on the recommended cut-
points from the Endocrine Society [21], as well as recom-
mendations from the Institute of Medicine (IOM) [22].
Moreover, due to the known seasonal variation of serum
25(OH)D [23], we statistically adjusted for the correspond-
ing season of blood draw. Intact serum PTH was analyzed
using a chemiluminescence assay. The reference range is
10–65 pg/mL, and the interassay coefficient of variation
was <4.3% at 36 pg/ml.
Statistical analysis
All statistical analyses were performed using SAS soft-
ware version 9.3 (SAS Institute, Cary, NC). Descriptive
characteristics were stratified by GMFCS (i.e. GMFCS
I-III and IV-V). Differences between GMFCS levels were
determined for general demographic and anthropometric
characteristics as well as vitamin D (25(OH)D) by an
independent-sample t-test, and difference in proportions
for sex by Chi-square test. Pearson product–moment
correlations were used to examine selected bivariate cor-
relations. A minimum criterion alpha level of p ≤ 0.05
was used to determine statistical significance. Data are
reported as means and standard deviations (SD). Linear
regression was used to determine differences in vitamin
D (25(OH)D) between GMFCS levels, seasons, and races.
This process was completed over several steps that re-
quired creating dummy codes for each season, race, and
GMFCS level (i.e., category). Thereafter, we examined
vitamin D status for differing categories by systematically
removing one category at a time (and thus creating an
interchangeable reference). Using this procedure, the β
coefficient for the intercept represented the mean of the
removed category, and the regression provided coeffi-
cients for each subsequent category, a standard error,
a t-value, and a p-value. Partial correlation and multiple
linear regression were also used to evaluate the associations
between vitamin D (25(OH)D), GMFCS, and various indi-
cators of adiposity, after controlling for multiple potential
moderating factors. In addition to the predictors, the fol-
lowing standard covariates were included in the original
model: age, sex, race, and season. A logistic model was also
fitted (i.e. using the PROC LOGISTIC procedure) with ex-
planatory variables to determine a best fit model for cat-
egorical vitamin D deficiency. Dummy coding was applied
to the categorical variables (e.g., GMFCS I-III = 0, GMFCS
IV-V = 1). Normality of the residuals was tested using a
Shapiro-Wilks test and homogeneity of the variance of theresiduals was tested with standard regression diagnostics.
Multicollinearity was tested using a variance inflation fac-
tor (VIF). Tests revealed no issues of collinearity for any
model. Initial model testing revealed that sex was not a pri-
mary predictor of vitamin D status (β = 0.09; p = 0.36), and
therefore we chose not to stratify by sex, but rather to in-
clude sex as a categorical variable in the final models.
Results
Subject characteristics
Characteristics of the study population are presented in
Table 1. Of the 112 patient records that were included in
the analysis, 53.6% were female (n = 60). GMFCS level
ranged from I-V, with the following breakdown (GMFCS I:
n = 9 [8.0%]; GMFCS II: n = 20 [17.9%]; GMFCS III: n = 29
[25.9%]; GMFCS IV: n = 29 [25.9%]; and GMFCS V:
n = 25 [22.3%]. Based on traditional cut points, approxi-
mately 52% of patients were overweight or obese (i.e.,
BMI ≥ 25 kg∙m−2), and of those, 23.5% were classified as
obese (i.e., BMI ≥ 30 kg∙m−2). Adults with GMFCS IV-V
were generally smaller in stature than GMFCS I-III.
Vitamin D level
The range for vitamin D level was from 5 to 64 ng/mL
(Table 1), and correlated to both parathyroid hormone
(PTH) (r = −0.24; p = 0.023) and WC (r = −0.40; p = 0.002).
Vitamin D was not correlated to age, BMI, WHR, or HC.
52 subjects (45.2%) were considered to have optimal levels
of vitamin D (>30 ng/mL); whereas 20.9% had insuf-
ficient levels (21–29 ng/mL); and 33.9% were deficient
(<20 ng/mL). There were no differences in vitamin D sta-
tus across levels of GMFCS (p = 0.092) (Figure 1). The
largest seasonal difference in vitamin D was between
winter and summer (β = −4.14 ng/mL), but was not signifi-
cant (p = 0.3067). African Americans had lower 25(OH)D
(β = −11.45; p = 0.02) than Non-Hispanic white subjects.
Multiple linear regression examining predictors of
vitamin D (25(OH)D) status identified WC (β = −0.27;
p < 0.001) (see: Figure 2 for Partial residual scatter plot)
as significant, controlling for age, sex, race, season, and
GMFCS (Table 2). These findings reveal that greater cen-
tral adiposity is associated with lower vitamin D status,
independent of motor impairment.
Logistic regression was conducted to identify the odds
of being deficient at the level published by the Endocrine
Society and IOM report [21,22], and revealed that for
every 10 cm increase in WC, the odds of being deficient
in vitamin D increase by a factor of 1.5 (95% CI: 1.062 -
1.974). According to sex-specific WC cutoffs, the odds
of being deficient increased by a factor of 3.5 (95% CI
1.12-11.0) for abdominal obesity.
Although a dichotomous cutoff for GMFCS was used
to create the motor impairment groups, 25(OH)D con-
centrations varied significantly. Thus, as an additional
Table 1 Descriptive characteristics of all adults with cerebral palsy, and differences between Gross Motor Function
Classification System (GMFCS) I-III and IV-V
Total Sample GMFCS I-III GMFCS IV-V p-value
N 112 58 54
Female. O 53.6 51.4 52.0 0.805
Age On) 34.00 (13.41) 32.95 (13.63) 36.10 (18.01) 0.224
Race/Ethnicity, %
Non-Hispanic White 90.4 87.9 92.3 0.45
African American 7.8 10.3 5.8 0.39
Mexican American or Other Hispanic 1.7 1.7 1.9 0.94
Body Mass (kg) 61.73 (25.09 72.35 (22.51) 51.02 4.73) <0.001*
Recumbent Length (cm) 159.21 (13.35) 161.65 (9.90) 155.68 (16.27) 0.043*
Body Mass Index (kg∙m-2) 25.86 (7.59) 28.72 (7.41) 22.79 (634) <0.001*
Obesity (BMI≥30), % 23.5 32.1 14.00 0.04*
Waist Circumference (cm) 85.53 (20.48) 92.80 (17.47) 79.20 (22.14) 0.003*
Hip Circumference (cm) 93.75 (17.23) 101.19 (1 3.10) 85.06 (18.57) <0.001*
Waist-to-Hip Ratio 0.90 (0.09) 0.90 (0.10) 0.90 (0.08) 0.74
25-hydroxyvitanin D (25(OH)D) (ng/mL) 30.17 (15.02) 27.53 (11.68) 31.71 (11.40) 0.143
Parathvroid hormone (PTH). (pg/mI) 49.8 (26.65) 47.96 (25.10) 52.63 (28.86) 0.418
*Significant difference between GMFCS I-III and IV-V (p <0.05).
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indicators of adiposity, we stratified subjects on the basis
of 25(OH)D quartiles (Table 3). Subjects with higher
vitamin D levels, across quartiles, had incrementally lower
WC measures.
Discussion
The primary finding of this investigation is that adults
with CP are at risk for insufficient and deficient serumFigure 1 Comparison of mean and individual 25-hydroxyvitamin D co
System (GMFCS). There were no significant differences between the levelvitamin D; however, vulnerability was not associated
with the severity of motor impairment. It is well known
that severely impaired individuals with CP experience
significant feeding issues and are at greater risk for mal-
nutrition, which are in-turn thought to be the primary
drivers of musculoskeletal fragility and altered growth
trajectories in this population. Interestingly, we found
that individuals classified in the highest severity category
(i.e., GMFCS V) had a similar serum vitamin D (25(OH)D)ncentrations across levels of Gross Motor Function Classification
s as assessed by linear regression.
Figure 2 Partial residual scatter plot for the variables waist circumference (WC) and 25-hydroxyvitamin D after controlling for the
effect of variables age, sex, and GMFCS (with 70% and 80% prediction ellipses).
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egory (i.e., GMFCS I) (27.9 ng/mL). This does not imply
that severity of motor impairment is unrelated to nutrition
status, growth, and/or bone health in CP; however, it does
highlight an independent factor that may pose an even
greater risk for vitamin D insufficiency. The overall preva-
lence of vitamin D insufficiency or deficiency was approxi-
mately 56%, which is similar to the typically-developed
adult population [21,24]. Interestingly, unlike the general
population [25], BMI was not associated with serum 25
(OH)D in this study.
Rather, abdominal obesity was the strongest predictor
for serum vitamin D in this heterogeneous sample of
adults with CP, even after adjusting for age, sex, race,
season, and level of motor function. Indeed, there is a
well-established link between vitamin D deficiency, ab-
dominal obesity and cardiometabolic risk [12,26], and
yet most studies do not account for at-risk populationsTable 2 General linear model to determine the independent a
circumference (WC) on vitamin D status, adjusting for age, se
Model predictor(s) β







Season -1.5with severe motor disabilities. Moreover, although several
studies have identified a general increased prevalence of
obesity among children with CP [27,28], the influence of
obesity on secondary health complications has yet to be
studied through the lifespan. It is of course logical to pre-
sume that the primary neurological insult associated with
CP is the underlying cause for impaired growth and risk
for musculoskeletal deterioration, but it is also likely that
excessive central adiposity may lead to exaggerated risk for
a non-CP, comorbid sequela as children with CP transition
into adulthood. The current findings clearly support the
need for greater clinical attention to assessments of serum
vitamin D status in all patients with CP. Particular atten-
tion should also be given to individuals with CP who are
African American, as vitamin D was significantly lower as
compared to Non-Hispanic white individuals.
Moreover, children and adults with CP have significantly
diminished lean body mass [29] and greater intermuscularssociation of functional impairment (GMFCS) and waist
x, GMFCS, Race and Season
SE t Pr > |t| Adjusted R2
0.19
6 l0.1 5.46 <0.001
0.13 0.59 0.55
6 3.23 -0.20 0.84
7 0.08 -3.35 <0.001
7 1.4 -0.32 0.74
4 4.02 -2.91 0.01
6 1.52 1.02 0.31
Table 3 Comparison of variables in quartiles of 25(OH)D concentration
Quartile 1 Quartile 2 Quartile 3 Quartile 4
p value
(n = 27) (n = 32) (n = 26) (n = 30)
25-hydroxnitamin D (25(OH)D) (ng/mL) 11.13 (3.51) 22.34 (3.85) 34.50 (3.62) 49.37 (8.10) NA
Age (yrs) 33.67 (15.6) 35.98 (13.87) 36.06 (12.56) 30.35 (1 L20) 0.317
Female (%) 44.00 26.67 18.30 36.67 0.082
GMFCS I-III (%) 29.31 25.86 25.86 18.97 0.201
GMFCS IV-V (%) 19.23 30.77 21.15 28.85 0.716
Body Mass (kg) 68.31 (28.3) 64.86 (21.37) 66.94 (23.28) 47.62 (22.79 0.006
Recumbent Length (cm) 158.35 (12.92) 159.14 (8.29) 161.99 (16.83) 157.3 (15.36) 0.684
Body Mass Index (kg∙m-2) 28.90 (9.9 M) 25.22 (7.23) 26.51 (6.18) 22.81 (5.47) 0.052
Waist Circumference (cm) 93.75 (19.06) 89.56 (24.73) 85.68 (17.01) 73.95 (15.60) 0.012
Hip Circumference (cm) 103.91 (17.34) 92.5 (13.62) 94.08 (12.77) 84.41 (19.78) 0.001
Parathyroid hormone (PTH). (pg/ml) 59.32 (32.87) 55.32 (26.83) 4 L89 (21.49) 40.84 (18.14) 0.036
p-value are presented to represent significant trend testing across quartiles.
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cations of skeletal muscle deterioration. Thus, even normal
BMIs in this population may disguise excess body fat
(i.e., “obesity misclassification” [31]), and risk for car-
diovascular and metabolic dysregulation. Based on stand-
ard BMI cutoffs, our data revealed that overweight and
obesity are common in adults with CP; however, BMI
was not associated with vitamin D status. This is congru-
ent with our previous work [20], and that of others [32]
which demonstrates that indicators of central adiposity
are potentially more sensitive for detecting standard clin-
ical markers of cardiometabolic risk (e.g. triglycerides,
HDL-cholesterol, total cholesterol to HDL cholesterol ra-
tio, LDL-cholesterol, HOMA-IR, etc..) in adults with CP.
Collectively, these findings support our ongoing conten-
tion that adults with CP are at higher risk for normal
weight obesity and cardiometabolic dysregulation [16],
and that indicators of central adiposity are superior to
BMI for risk stratification. This is not surprising consid-
ering the mounting evidence in support of this diagnostic
paradigm shift, even among the general population [33],
and thus clinicians should be aware of the appropriate
gender- and race/ethnicity-specific recommended waist
circumference thresholds for abdominal obesity [34,35].
In the general population, recent data have also re-
vealed a link between vitamin D and preservation of
muscular strength [36]. This may have significant impli-
cations for individuals with CP over the lifespan, as even
children with CP have impaired recruitment of target
musculature during voluntary activity, and an over-
recruitment and co-activation of antagonist musculature
[37]. Premature sarcopenia and muscular weakness in CP
are suggested to translate to acute functional deficit and
disability [38]. As a result, functional loss, especially of mo-
bility, is a major issue in adults with CP. The minority ofindividuals that actually report preservation of mobility
throughout adulthood accredit this to maintenance of
strength, balance and overall fitness. It is therefore critical
to gain a greater understanding of how treatment of such
modifiable risk factors as vitamin D deficiency could im-
pact long term preservation of functional capacity and ac-
tivity participation.
An obvious limitation in this study is that we could
not account for dietary intake of calcium or vitamin D.
Thus, it is possible that more severely affected individ-
uals were adhering to a stricter regimen of nutrient
supplementation (as is commonly recommended with
anticonvulsant therapies), which would explain the lack of
differences across GMFCS levels. Future research should
account for nutrient intake, as well as any medication that
may interfere with calcium and vitamin D. Further, as with
all cross-sectional investigations, a limitation of this study
is the inability to disentangle the cause-effect relationship
between predictors and outcomes. Perhaps just as import-
antly, with this design we were unable to examine numer-
ous potential mediators that were not measured. For
example, no measures of muscle strength were made, and
thus although vitamin D status was not associated with
GMFCS in this study, it is possible that vitamin D status
may affect muscle strength differently among individ-
uals with more severe mobility impairments. It is also
plausible that vitamin D deficiency may lead to diminished
vitamin D receptor (VDR) in type II muscle fiber (see re-
cent review [39]), and thus have a direct influence on mus-
cular weakness, or conversely, strength improvement, with
supplementation [40].
Conclusions
This is one of the largest studies to examine vitamin D
status in a heterogeneous sample of adults with CP, and
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abdominal obesity. Further, our finding that vitamin D
status was not linked with GMFCS is novel and import-
ant, as degree of motor impairment tends to be the clin-
ical scapegoat of secondary problems for this population.
Unfortunately, there is still a large gap between the basic
research intended to uncover novel etiologic factors and
treatments of CP, and that which occurs at the transla-
tional level to understand secondary mechanisms or
complications unique to this population. Clinical re-
search tends to focus on common symptoms such as
pain, spasticity, and mobility issues, and the viability and
effectiveness of respective medical interventions. There
has been very little attention directed at understanding
the predictors of musculoskeletal pathology or cardio-
metabolic risk in patients with CP through the lifespan.
Future research is certainly warranted to examine the
appropriate timing and dosing of supplemental vitamin
D in children and adults with CP, as well as identifying
optimal behavioral interventions to reduce risk of ab-
dominal obesity.
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